Estimates for 2012 have decreased today on Yahoo Finance. For Q1, now 0.86 (reduced from 0.91) and for full year $4.50 (reduced from $4.64). Not sure if this really matters given that continual increases in earnings estimates a few months ago did not prevent the share price from falling and when Vertex massively beat estimates the last two quarters, the stock price went down. At least it will be easier for Vertex to meet or beat estimates going forward. Apparently, unlike most stocks where earnings mean everything, the only thing that seems to matter in the minds of those making bets big enough to move the stock price is whether or not Vertex can maintain significant HCV revenues beyond 2014.